While it is known that severe acute respiratory coronavirus 2 (SARS-CoV-2) infection often starts with 1--2 days of asymptomatic shedding before a person gets sick, there are limited data about the biological source and duration of viral shedding after symptom resolution in recently infected individuals. Besides respiratory droplets, SARS-CoV-2 RNA has been isolated in other biological samples including urine, blood, feces, and saliva \[[@CIT0001], [@CIT0002]\]. The expression of SARS-CoV-2 receptor angiotensin 2--converting enzyme (ACE2) across multiple tissues also suggests that SARS-CoV-2 could be found in other tissues and body fluids \[[@CIT0003]\], including in the testis and male genital tract \[[@CIT0004], [@CIT0005]\]. Very few studies exist on the presence of SARS-CoV-2 RNA in semen, and these studies have been limited by considerable time between semen sampling and diagnosis of active infection. In particular, when semen has been examined \~4--6 weeks after SARS-CoV-2 infection, the virus was not detected, and a case report of a single male acutely infected revealed no SARS-CoV-2 in seminal fluid \[[@CIT0006]\]. Whether SARS-CoV-2 can be detected in semen during the acute phase of SARS-CoV-2 infection when the virus is concomitantly present in nasal and/or oral secretions remains a concern. Here, we evaluated the presence and level of SARS-CoV-2 in paired semen, nasal secretion, and saliva samples collected in the short and medium term after confirmed SARS-CoV-2 symptomatic infections.

METHODS {#s1}
=======

Patient Consent Statement {#s2}
-------------------------

All participants provided informed, written consent. This study was conducted under a protocol for collecting samples from persons with known SARS-CoV-2 infection approved by the Institutional Review Board of University of California San Diego.

Study Cohort and Sampling {#s3}
-------------------------

Men who had been diagnosed with SARS-CoV-2 based on a combination of medical history, symptoms, and the presence of SARS-CoV-2 RNA in the upper respiratory tract were invited to enroll in this study. All participants were outpatients at the time of enrollment and sample collection. They were instructed to self-collect saliva (passive drool), nasal swab, and semen by masturbation without lubricant after 24 hours of abstinence. Samples were collected within 1--3 weeks after the onset of symptoms.

Processing of Semen Samples {#s4}
---------------------------

Semen was processed as in Butler et al. \[[@CIT0009]\]. Briefly, viral transport medium (2 mL of RPMI 1640 with 2 mMol/L of glutamine and 10% fetal bovine serum \[FBS\], with the addition of 100 U/mL of penicillin, 100 μL/mL of streptomycin, and 200 U/mL of nystatin) was added to seminal samples at collection. Seminal plasma was separated from seminal cells by centrifugation at 700 × *g* for 12 minutes within 4 hours of collection and stored at −80°C and −150°C, as previously described \[[@CIT0009]\].

SARS-CoV-2 RNA Extraction {#s5}
-------------------------

RNA was extracted from seminal plasma, saliva, and viral transport media that contained the nasopharyngeal (NP) swab; 140 µL of each type of sample was extracted for RNA using Qiagen's QIAamp Viral RNA mini kit (cat\# 52904) according to the manufacturer's recommendation. cDNA from SARS-CoV-2 RNA was generated using the Bio-Rad One-Step RT-ddPCR Advanced Kit for Probes (cat\# 186--4021).

### SARS-CoV-2 RNA Detection and Quantification {#s6}

Qualitative tests for SARS-CoV-2 were performed on the first collected nasal/NP specimen for diagnostic confirmation using the FluxErgy platform (Irvine, CA, USA), which is currently available as a Research Use Only (RUO) or Investigational Use Only (IUO) device for the development of new diagnostic products.

Quantitative measure of SARS-CoV-2 in saliva and semen was performed using digital droplet polymerase chain reaction (ddPCR; BIO-RAD QX200 Droplet Reader). Copy numbers were calculated as the mean of 3 replicates. Briefly, we have adapted our validated protocol \[[@CIT0010]\] to quantify SARS-CoV-2 in various samples following the Centers for Disease Control and Prevention recommendations and the 2019-nCoV Real-Time RT-PCR Diagnostic Panel targeting the virus nucleocapsid (N) and the ORF gene \[[@CIT0011]\]. Based on testing and dilutions with known positive and negative clinical samples (data not shown), the current level of detection is 0.05 copies/µL.

RESULTS {#s7}
=======

A total of 6 participants aged 28--45 years were enrolled in this study ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). All initially presented with clinical symptoms compatible with SARS-CoV-2 and/or recent history of close contact with a confirmed case. Symptoms included cough, shortness of breath, fever, myalgia, fatigue, anosmia, headache, anorexia, and diarrhea.

Before enrollment, 5/6 participants tested positive for SARS-CoV-2 RNA on NP swab samples collected within 1--3 days following the onset of symptoms. ID16 was not initially tested by his clinical team, but the diagnosis was supported by both clinical symptoms and recent close contact with a confirmed case. Upon enrollment in the study, the diagnosis of active SARS-CoV-2 infection was confirmed by positive PCR on NP swab on day 6 post--symptom onset. The clinical conditions of all participants improved, with complete resolution of initial symptoms, within 1--3 weeks from the onset.

Paired saliva and semen samples were collected a mean of 12 days (6--17 days) after the onset of symptoms, and ddPCR was performed to quantify the SARS-CoV-2 level in all samples. Half of the participants also had research nasal swabs performed. All 6 semen samples were negative for SARS CoV-2 (≤0.03 copies/µL), while SARS-CoV-2 was still detected in all saliva samples (6 participants) and all research nasal swabs (3 participants). Saliva levels of virus were quantified and varied from 0.05 to 679 copies/µL of input saliva ([Figure 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}).

![Sampling and SARS-CoV-2 testing history. See Table 1 for quantitative measures via digital droplet polymerase chain reaction. Abbreviation: NP, nasopharyngeal.](ofaa325f0001){#F1}

###### 

Digital Droplet PCR Measures of SARS-CoV-2 in Paired Saliva, Nasal Secretion, and Semen

  Participant ID   Copies/µL of Saliva (Days From Onset)   Repeat, Experimental Nasal Swab (Days From Onset)   Copies/µL of Semen (Days From Onset)
  ---------------- --------------------------------------- --------------------------------------------------- --------------------------------------
  ID6              0.12 (15)                               Not done                                            ≤0.03 (16)
  ID8              0.05 (16)                                                                                   ≤0.03 (17)
  ID10             63.9 (6)                                                                                    ≤0.03 (9)
  ID14             679 (14)                                Positive (14)                                       ≤0.03 (14)
  ID16             11.8 (5)                                Positive (6)                                        ≤0.03 (6)
  ID17             12.7 (7)                                Positive (7)                                        ≤0.03 (7)

Abbreviation: PCR, polymerase chain reaction.

DISCUSSION {#s8}
==========

The temporal dynamic of viral shedding and transmissibility of SARS-CoV-2 remains a major concern to control the spread of the virus and directly impacts control measures such as isolation, contact tracing, and enhanced hygiene or use of face masks for symptomatic persons. Recent studies have shown persistant viral detection in the upper respiratory tract up to 37 days after the onset of symptoms \[[@CIT0012]\]. ACE2 expression across tissues and body fluid---including seminal fluid---suggests possible extrarespiratory transmission routes \[[@CIT0013]\]. Here, we investigated the presence of SARS-CoV-2 in the semen of men in whom virus was demonstrably present in the respiratory tract. We found no evidence of SARS-CoV-2 in semen collected 6--17 days after the onset of symptoms despite all men having concomitant shedding of virus in oral secretions up to 792 copies/µL. Though the study is small in number, it adds to available literature that the male genital tract does not appear to be a site where SARS-CoV-2 is shed in either the acute or late phase of infection. Identifying whether SARS-CoV-2 can be shed in semen has implications for public health, as all predominant modes of transmission (ie, droplet, sexual contact, airborne, fomite, etc.) need to be identified in order to help curb the spread of the virus. With the small number of participants in this study, it is difficult to quantify the absolute probably of spread in a large population, but the complete absence of virus using ultrasensitive methods suggests that shedding of the virus in semen is certainly not common. A larger study would be needed to demonstrate and quantify rare events of shedding.

Whether SARS-CoV-2 can be detected in the semen at the very early phase of infection or during the incubation period when it is present in the upper respiratory tract \[[@CIT0012]\] would require further investigation, but collective evidence \[[@CIT0006]\] and our study suggest that SARS-CoV-2 is not present in semen.

Supplementary Data {#s9}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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